NASD · Healthcare · Medical Devices · USA
Bioventus Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.
Bioventus is a global medical device company addressing musculoskeletal challenges through three business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies. Its portfolio includes hyaluronic acid injections for knee osteoarthritis, peripheral nerve stimulation devices, ultrasonic surgical systems, and bone graft substitutes. The company serves physicians in the U.S. and international markets across office, surgical center, and hospital settings.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Bioventus Inc stock.
Undervalued: intrinsic value $21.39 per share, market price $10.60, margin of safety 50.4% (as of 2026-11-17).
Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $21.39; the price of $10.60 is 50% below that value, and 79% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
BVS is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $21.39; the price of $10.60 is 50% below that value, and 79% of that value comes from beyond year five.
$21.39 per share (as of the 2026-11-17 close), against a market price of $10.60. That is a margin of safety of 50.4%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.